Skip to main content

Health condition · Clinically reviewed

Neuromyelitis optica, a rare but treatable cause of severe vision and spinal cord attacks.

Distinct from multiple sclerosis, driven in most cases by AQP4 antibodies. Early diagnosis and preventative treatment change the outcome.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NHS England specialist commissioning, NICE and peer-reviewed neurology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including AQP4 antibody testing and specialist-commissioned biologic therapy.

Key facts

NMOSD at a glance.

The essentials, in plain English - what it is, how it differs from MS, and how it’s diagnosed and treated in the UK today.

  • What it is

    A rare autoimmune disease of the central nervous system that attacks the optic nerves and spinal cord, distinct from multiple sclerosis.

  • Underlying antibody

    Most people have antibodies against aquaporin-4 (AQP4), a water channel on astrocytes - this drives the attack pattern.

  • Not the same as MS

    NMOSD relapses tend to be more severe with worse recovery, and it needs different long-term treatment to multiple sclerosis.

  • Classic presentation

    Severe optic neuritis (often both eyes), a long spinal cord lesion, or intractable hiccups and vomiting from area postrema involvement.

  • Diagnosis

    AQP4 antibody blood test plus MRI showing a longitudinally extensive spinal cord lesion, with MOG antibody testing to exclude a related condition.

  • Treatment goal

    Prevent relapses at almost any cost - each attack can leave permanent disability, so long-term immunosuppression is started early.

Why this guide matters

Every attack counts, so speed matters.

NMOSD is rare, frequently misdiagnosed as MS, and unforgiving of delay. The three points below shape everything else on this page.

  • It is not multiple sclerosis

    NMOSD needs its own diagnostic pathway and treatment plan - some MS medicines can make it worse, so getting the diagnosis right matters.

  • Recovery from attacks is often incomplete

    Unlike MS, disability accumulates mainly through relapses - preventing the next attack is the priority, not just treating the current one.

  • Modern treatment has changed outcomes

    Specialist-commissioned biologics have made relapse-free years achievable for many people - early referral gives the best chance of this.

How the diagnosis is made

From first attack to a specialist plan.

The steps a UK neurology team will normally follow, in order - so you know what to expect and why speed matters.

  1. 01

    Recognising

    Recognising the attack

    Sudden, severe visual loss, weakness or numbness spreading over days, or unexplained persistent hiccups and vomiting prompt urgent assessment.

  2. 02

    Recognising

    Urgent MRI brain and spine

    Looking for a longitudinally extensive transverse myelitis lesion (spanning three or more vertebral segments) and optic nerve or area postrema changes.

  3. 03

    Recognising

    AQP4 antibody test

    A blood test for aquaporin-4 antibodies, ideally using a cell-based assay - positive in most, but not all, people with NMOSD.

  4. 04

    Confirming

    MOG antibody test

    Checked to exclude MOG antibody disease (MOGAD), a related but distinct condition with a different treatment and prognosis.

  5. 05

    Confirming

    Lumbar puncture and bloods

    Cerebrospinal fluid analysis and screening for coexisting autoimmune conditions such as lupus or Sjögren's syndrome.

  6. 06

    Planning

    Specialist neuroimmunology referral

    Confirmed or suspected NMOSD is managed by a specialist neuroimmunology centre, often via NHS England highly specialised commissioning.

  7. 07

    Planning

    Long-term treatment plan

    Once confirmed, a preventative immunosuppressive therapy is chosen and started as early as possible to reduce relapse risk.

Typical timeline: urgent assessment within days, a confirmed diagnosis and treatment plan within weeks.

Symptoms

What an NMOSD attack actually looks like.

The classic triad of severe optic neuritis, long spinal cord lesions and area postrema syndrome - and the features that mean it’s time to escalate.

  • Severe optic neuritis

    Sudden, often bilateral, severe visual loss with eye pain - recovery is frequently incomplete, unlike typical MS-related optic neuritis.

  • Longitudinally extensive myelitis

    Weakness, numbness, bladder and bowel dysfunction from a long spinal cord lesion - can progress rapidly over hours to days.

  • Area postrema syndrome

    Intractable hiccups, nausea and vomiting lasting more than 48 hours - an under-recognised but classic presenting feature.

  • Bladder and bowel dysfunction

    Urinary retention or incontinence often accompanies spinal cord attacks and can be an early clue.

  • Brainstem symptoms

    Double vision, vertigo, facial weakness or difficulty swallowing when the attack involves the brainstem.

  • Narcolepsy-like symptoms

    Excessive daytime sleepiness or sudden sleep attacks can occur with hypothalamic involvement, though this is uncommon.

  • Poor recovery between attacks

    Unlike MS, disability in NMOSD accumulates mainly through relapses rather than gradual progression - each attack matters.

  • Red flag - bilateral vision loss

    Rapid, severe, bilateral visual loss or a long spinal cord lesion should prompt same-day neurology assessment.

Treatment

How NMOSD is treated in the UK.

Acute relapses need urgent steroids and sometimes plasma exchange - long-term, specialist-commissioned biologics prevent the next attack.

  • High-dose IV steroids

    Methylprednisolone for five days is first-line for acute relapses, started as early as possible to limit permanent damage.

  • Plasma exchange

    Used when steroids alone are insufficient or the attack is severe - removes circulating AQP4 antibodies from the blood.

  • Rituximab

    An anti-CD20 monoclonal antibody that depletes B cells - a widely used first-line preventative therapy, NHS specialist-commissioned.

  • Eculizumab

    A complement inhibitor licensed for AQP4-positive NMOSD - highly effective at reducing relapse but requires meningococcal vaccination first.

  • Satralizumab

    An interleukin-6 receptor inhibitor given by subcutaneous injection - another specialist-commissioned option for relapse prevention.

  • Azathioprine or mycophenolate

    Older immunosuppressants still used in some centres, particularly where biologic access is limited or not yet established.

  • Avoiding disease-modifying MS drugs

    Some standard MS therapies (such as interferon-beta and natalizumab) can worsen NMOSD, which is why accurate diagnosis matters so much.

  • Rehabilitation and symptom control

    Physiotherapy, bladder management and pain control support recovery and quality of life alongside disease-modifying treatment.

What this guide is based on

The sources behind every claim on this page.

UK national commissioning policy and international consensus diagnostic criteria, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your neurologist knows your history and antibody status and can tell you which parts apply to you. If in doubt, get seen urgently.

  • NHS England. Clinical Commissioning Policy: Treatments for neuromyelitis optica spectrum disorder (NMOSD).

  • National Institute for Health and Care Excellence (NICE). Technology appraisals for eculizumab and satralizumab in NMOSD.

  • Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

  • Association of British Neurologists. Guidance on neuromyelitis optica spectrum disorder management.

Red flags

When NMOSD needs urgent attention.

Every relapse can leave permanent damage. These are the situations where urgent neurology assessment cannot wait.

  • Sudden bilateral visual loss

    Rapid, severe loss of vision in both eyes is a neurological emergency requiring same-day assessment and urgent steroid treatment.

  • Rapidly progressive limb weakness

    Worsening weakness or numbness over hours suggests an active spinal cord attack - do not wait for it to settle on its own.

  • Unexplained persistent hiccups

    Hiccups or vomiting lasting more than 48 hours without a gastrointestinal cause can be the first sign of an NMOSD attack.

  • New bladder or bowel dysfunction

    Sudden urinary retention or incontinence alongside limb symptoms points to spinal cord involvement needing urgent imaging.

  • Breathing difficulty

    A high spinal cord lesion can affect the muscles of breathing - any breathlessness alongside neck-level symptoms needs emergency care.

  • Missed or delayed diagnosis

    Recurrent 'optic neuritis' or 'transverse myelitis' episodes without an AQP4 antibody test warrant specialist neuroimmunology review.

  • Starting the wrong medication

    Certain MS disease-modifying drugs can worsen NMOSD - confirming the diagnosis before starting long-term treatment is essential.

  • Pregnancy considerations

    NMOSD relapse risk can change in pregnancy and postpartum - specialist neurology and obstetric input should be arranged early.

  • Infection before biologic therapy

    Live vaccines and certain infections need careful timing around rituximab, eculizumab or satralizumab - discuss with the specialist team.

Living with it

A rare disease, with a clear treatment ladder.

Four things that make the biggest difference day to day - knowing your warning signs, staying on treatment, rehabilitation and specialist support.

A quiet reminder

Preventing the next attack is the whole strategy.

Staying on preventative treatment, even when feeling well, is what keeps NMOSD quiet.

  1. 01 Vigilance

    Know your own warning signs

    Learn the early symptoms of a relapse - new visual change, limb weakness or unexplained hiccups - and seek urgent review rather than waiting.

  2. 02 Adherence

    Stay on preventative treatment

    Missing doses of rituximab, eculizumab or satralizumab raises relapse risk - work with your team if side effects or access become a problem.

  3. 03 Support

    Rehabilitation matters

    Physiotherapy, occupational therapy and bladder management can meaningfully improve day-to-day function after an attack.

  4. 04 Connect

    Find specialist and peer support

    NMOSD is rare - specialist neuroimmunology centres and patient organisations offer expertise and community that a general clinic may not.

Frequently asked

Everything we get asked about NMOSD.

Quick answers on antibodies, diagnosis, MS comparisons and specialist treatment.

  • What is neuromyelitis optica spectrum disorder?

    NMOSD is a rare autoimmune condition in which the immune system attacks the optic nerves and spinal cord, and sometimes the brainstem. Most people have antibodies against aquaporin-4 (AQP4), a protein on cells that support the nervous system.

  • Is NMOSD the same as multiple sclerosis?

    No. Although both cause optic neuritis and spinal cord inflammation, NMOSD is a distinct disease with its own antibody, imaging pattern and treatment approach. Attacks in NMOSD tend to be more severe with less complete recovery, and some MS medicines can make NMOSD worse.

  • What is area postrema syndrome?

    It is intractable hiccups, nausea or vomiting lasting more than 48 hours, caused by inflammation in a part of the brainstem called the area postrema. It is an easily missed but classic early feature of NMOSD.

  • How is NMOSD diagnosed?

    Through a combination of typical symptoms, an MRI showing a long spinal cord lesion or optic nerve involvement, and a blood test for AQP4 antibodies. MOG antibody testing is also done to rule out a related condition called MOGAD.

  • How is NMOSD treated?

    Acute relapses are treated with high-dose intravenous steroids and sometimes plasma exchange. Long-term, specialist-commissioned therapies such as rituximab, eculizumab or satralizumab are used to prevent further attacks, since recovery from each relapse is often incomplete.

  • Can NMOSD be cured?

    There is currently no cure, but modern preventative treatments have transformed outcomes by substantially reducing relapse frequency. Early diagnosis and starting treatment before further attacks occur gives the best chance of preserving function.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.